Other Events ·
Enlivex cuts workforce by 60% and slashes CEO pay 40% to fund Phase 2b trial
ENLVEnlivex Ltd.
Enlivex announced an immediate cost reduction plan designed to lower cash burn and concentrate resources on its Phase 2b clinical trial of Allocetra for knee osteoarthritis. The company is winding down all non-clinical R&D activities, reducing its workforce by approximately 60%, cutting management salaries by 20%, and lowering the CEO's compensation by 40%. Topline six-month data from the trial is expected by mid-2027. Enlivex operates in the biotechnology sector, developing immunotherapies for aging-related conditions while maintaining a digital asset treasury strategy.